Source comparison
Does Melanotan-2 Help Libido Research? Comparison of Mechanisms
| Compound | Primary Mechanism | Onset Time | Duration | Effect on Arousal (Central) | Effect on Erectile Function (Peripheral) | Research Evidence Level ||—|—|—|—|—|—|| Melanotan-2 | MC4R/MC3R agonist (hypothalamic activation) | 45–90 minutes | 6–12 hours | D
This comparison does not assign a generated winner or score.
- | Compound | Primary Mechanism | Onset Time | Duration | Effect on Arousal (Central) | Effect on Erectile Function (Peripheral) | Research Evidence Level ||—|—|—|—|—|—|| Melanotan-2 | MC4R/MC3R agonist (hypothalamic activation) | 45–90 minutes | 6–12 hours | Direct increase via dopamine modulation | Indirect via central arousal pathways | Phase II trials, multiple RCTs || Sildenafil (Viagra) | PDE5 inhibitor (nitric oxide potentiation) | 30–60 minutes | 4–6 hours | None. Requires external arousal stimulus | Direct vasodilation in corpus cavernosum | FDA-approved, extensive Phase III data || Bremelanotide | MC4R agonist (same pathway, different structure) | 30–45 minutes | 8–10 hours | Direct increase, female-focused trials | Moderate peripheral enhancement | FDA-approved for HSDD in women || Testosterone (exogenous) | Androgen receptor activation | 48–72 hours (plasma peak) | Weeks to months | Gradual increase via androgen signaling | Indirect via libido restoration | Standard care for